teclistamab Archives - PharmaDeviceNews

Johnson & Johnson strengthens its multiple myeloma franchise with TECVAYLI and DARZALEX FASPRO approval. What clinicians are watching next

By Pallavi Madhiraju on March 9, 2026 Pharma & Biotech

FDA approves TECVAYLI plus DARZALEX FASPRO for relapsed multiple myeloma. Discover what the MajesTEC-3 data means for future immunotherapy strategies.

J&J’s Tecvayli-Darzalex Faspro combination approved for myeloma after MajesTEC-3 Phase 3 results

By Pallavi Madhiraju on March 6, 2026 Pharma & Biotech

FDA approves J&J’s teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.

MajesTEC-3 results put Johnson & Johnson’s bispecific combo at center of myeloma care debate

By Pallavi Madhiraju on December 9, 2025 Pharma & Biotech

TECVAYLI and DARZALEX FASPRO show major survival benefits in second-line multiple myeloma. Find out what the MajesTEC-3 trial means for clinical practice.